SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Get Free Report)’s share price crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $65.67 and traded as high as $67.45. SPDR S&P Pharmaceuticals ETF shares last traded at $67.37, with a volume of 639,639 shares changing hands.
SPDR S&P Pharmaceuticals ETF Price Performance
The business has a 50-day moving average of $65.67 and a 200 day moving average of $61.97. The company has a market cap of $501.91 million, a PE ratio of 14.28 and a beta of 0.62.
Institutional Investors Weigh In On SPDR S&P Pharmaceuticals ETF
A number of large investors have recently made changes to their positions in XPH. Wharton Business Group LLC purchased a new position in shares of SPDR S&P Pharmaceuticals ETF in the third quarter worth approximately $3,016,000. Simplex Trading LLC bought a new stake in SPDR S&P Pharmaceuticals ETF during the third quarter valued at approximately $190,000. Allspring Global Investments Holdings LLC bought a new stake in SPDR S&P Pharmaceuticals ETF during the third quarter valued at approximately $364,000. Commonwealth Equity Services LLC bought a new stake in SPDR S&P Pharmaceuticals ETF during the third quarter valued at approximately $442,000. Finally, Team Financial Group LLC bought a new stake in SPDR S&P Pharmaceuticals ETF during the third quarter valued at approximately $65,000.
About SPDR S&P Pharmaceuticals ETF
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
